Archive: Company News

Company News: Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge

– Final panel demonstrates overall weighted average sensitivity of 91.4% and overall weighted average specificity of 99.5% across all lower respiratory tract panel pathogens

– Unyvero results available after approximately five hours only, compared to three to four days on average for microbiology culture based methods

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration for its Unyvero Platform and the Unyvero LRT Lower Respiratory Tract Cartridge.

Read more…

Company News: Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections; Presents at Key Investor and Scientific Conferences in Q1, 2017

– Highly multiplexed panel covers up to 112 diagnostic targets

– Third new panel developed within one year after IPO

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the completion of development of its fourth Application Cartridge.

Read more…

Company News: BioNTech to Present at 35th Annual J.P. Morgan Healthcare Conference 2017

BioNTech AG, a fully integrated biotechnology company developing truly individualized cancer immunotherapies, today announced that Sean Marett, COO of BioNTech, will be presenting at 35th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA January 9 – 12, 2017. The presentation is scheduled for Wednesday, January 11th at 9:30 AM Pacific Standard Time. Mr. Marett will provide an overview of the company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer vaccines and the establishment of a second mRNA production facility at the Company´s headquarters in Germany.

The J.P. Morgan Healthcare Conference brings together corporate leaders, financial sponsors and institutional investors to explore market and sector trends.

Company News: Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec

– Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-answer molecular diagnostic testing

– Gyronimo to be fully integrated into Unyvero Platform and suite of products

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the acquisition of the real-time qPCR-based Gyronimo Platform from Carpegen GmbH and Systec GmbH, joint owners of the platform.

Read more…

1 83 84 85 160